A minimal standardized human bone marrow microphysiological system to assess resident cell behavior during normal and pathological processes.


Journal

Biomaterials science
ISSN: 2047-4849
Titre abrégé: Biomater Sci
Pays: England
ID NLM: 101593571

Informations de publication

Date de publication:
18 Jan 2022
Historique:
pubmed: 15 12 2021
medline: 21 1 2022
entrez: 14 12 2021
Statut: epublish

Résumé

Bone marrow is a complex and dynamic microenvironment that provides essential cues to resident cells. We developed a standardized three-dimensional (3D) model to decipher mechanisms that control human cells during hematological and non-hematological processes. Our simple 3D-model is constituted of a biphasic calcium phosphate-based scaffold and human cell lines to ensure a high reproducibility. We obtained a minimal well-organized bone marrow-like structure in which various cell types and secreted extracellular matrix can be observed and characterized by

Identifiants

pubmed: 34904143
doi: 10.1039/d1bm01098k
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

485-498

Auteurs

Thibault Voeltzel (T)

CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, 69000 Lyon, France.
Inserm U1052, Centre de Recherche en Cancérologie de Lyon, 69000 Lyon, France.
Université de Lyon, 69000, Lyon, France.
Department of Cancer Initiation and Tumor cell Identity and Lyon, France.
CNRS GDR 3697 MicroNiT, Tours, France. thibault.voeltzel@inserm.fr.

Gaëlle Fossard (G)

CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, 69000 Lyon, France.
Inserm U1052, Centre de Recherche en Cancérologie de Lyon, 69000 Lyon, France.
Université de Lyon, 69000, Lyon, France.
Department of Cancer Initiation and Tumor cell Identity and Lyon, France.
Hospices Civils de Lyon, Hematology Department, Centre Hospitalier Lyon Sud, F-69495 Pierre Bénite, France.

Michaël Degaud (M)

CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, 69000 Lyon, France.
Inserm U1052, Centre de Recherche en Cancérologie de Lyon, 69000 Lyon, France.
Université de Lyon, 69000, Lyon, France.
Department of Cancer Initiation and Tumor cell Identity and Lyon, France.
Hospices Civils de Lyon, Hematology Department, Centre Hospitalier Lyon Sud, F-69495 Pierre Bénite, France.

Kevin Geistlich (K)

CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, 69000 Lyon, France.
Inserm U1052, Centre de Recherche en Cancérologie de Lyon, 69000 Lyon, France.
Université de Lyon, 69000, Lyon, France.
Department of Cancer Initiation and Tumor cell Identity and Lyon, France.
Centre Léon Bérard, Lyon, France.

Nicolas Gadot (N)

CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, 69000 Lyon, France.
Inserm U1052, Centre de Recherche en Cancérologie de Lyon, 69000 Lyon, France.
Université de Lyon, 69000, Lyon, France.
Research Pathology Platform, Department of Translational Research and Innovation, Centre Léon Bérard, Lyon, France.

Sandrine Jeanpierre (S)

CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, 69000 Lyon, France.
Inserm U1052, Centre de Recherche en Cancérologie de Lyon, 69000 Lyon, France.
Université de Lyon, 69000, Lyon, France.
Department of Cancer Initiation and Tumor cell Identity and Lyon, France.
Centre Léon Bérard, Lyon, France.

Ivan Mikaelian (I)

CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, 69000 Lyon, France.
Inserm U1052, Centre de Recherche en Cancérologie de Lyon, 69000 Lyon, France.
Université de Lyon, 69000, Lyon, France.
Department of Cancer Initiation and Tumor cell Identity and Lyon, France.

Marie Brevet (M)

Pathology Department, Hospices Civils de Lyon, Bron F-69500, France.

Adrienne Anginot (A)

UMR1197, Université Paris-Saclay, 94800 Villejuif, France.
CNRS GDR 3697 MicroNiT, Tours, France. thibault.voeltzel@inserm.fr.

Marie-Caroline Le Bousse-Kerdilès (MC)

UMR1197, Université Paris-Saclay, 94800 Villejuif, France.
CNRS GDR 3697 MicroNiT, Tours, France. thibault.voeltzel@inserm.fr.

Valérie Trichet (V)

INSERM, UMR 1238, PHYOS, Faculty of Medicine, University of Nantes, Nantes, France.
CNRS GDR 3697 MicroNiT, Tours, France. thibault.voeltzel@inserm.fr.

Sylvain Lefort (S)

CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, 69000 Lyon, France.
Inserm U1052, Centre de Recherche en Cancérologie de Lyon, 69000 Lyon, France.
Université de Lyon, 69000, Lyon, France.
Department of Cancer Initiation and Tumor cell Identity and Lyon, France.
CNRS GDR 3697 MicroNiT, Tours, France. thibault.voeltzel@inserm.fr.

Véronique Maguer-Satta (V)

CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, 69000 Lyon, France.
Inserm U1052, Centre de Recherche en Cancérologie de Lyon, 69000 Lyon, France.
Université de Lyon, 69000, Lyon, France.
Department of Cancer Initiation and Tumor cell Identity and Lyon, France.
CNRS GDR 3697 MicroNiT, Tours, France. thibault.voeltzel@inserm.fr.
Centre Léon Bérard, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH